2024 PROGRAM NEWSLETTER

6TH ANNUAL

EGFR RESISTERS RESEARCH SUMMIT

An academic research summit focusing on the advancement of EGFRm treatment paradigms through meaningful collaboration between physician scientist investigators and patients

cec HEALTHCARE EDUCATION | EGFR esisters

Presented by the EGFR Resisters and Creative Educational Concepts LLC
Supported through an independent educational grant from AstraZeneca

2024 EGFR Resisters Research Summit Recap

2024 EGFR-RRS Faculty & Young Investigators

The 6th Annual EGFR Resisters Research Summit was convened December 12–13, 2024, in Louisville, Kentucky. The summit kicked off with a welcome dinner on Thursday evening, when the young investigators heard from Jill Feldman, co-founder of the EGFR Resisters, who introduced the participants to the mission of the EGFR Resisters patient group, the history of the summit, and the critical need for continued advancements in research into EGFR-mutant non–small cell lung cancer (NSCLC). This year, we also honored the memory of patient advocate, co-founder of the EGFR Resisters group, and one of the original founders of the EGFR Resisters Research Summit, Ivy Elkins.

On Friday morning, we started the main day of the program with a presentation from Diane Legg, a patient advocate and founder of the LUNGstrong Foundation, who shared her 20-year journey with lung cancer and emphasized the need for more effective and better tolerated lung cancer treatments. We then dived into an exciting day of research presentations by the young investigators. Over the course of the day, our 15 young investigators presented on a wide variety of research projects, ranging from lab-based basic science work focused on the biology of EGFR-mutant cancer to clinical case series evaluating the efficacy of various treatments for patients with brain metastases to clinical trials evaluating novel therapies. The investigators fielded questions and received feedback from the panel of expert judges, patient advocates, and their peers. The judges were uniformly impressed by the investigators' work and excellent presentation skills.

Throughout the day, small group breakout sessions allowed for mentoring and networking between participants and mentors in a smaller, more intimate setting. Topics of discussion ranged from searching for jobs after fellowship, grant funding, work-life balance, and many others. As in the past, these small group sessions were a highlight of the program for both young investigators and faculty, who enjoyed the opportunity to forge connections that we will hope will last long after the summit.

The EGFR Resisters Research Summit concluded with an awards ceremony and dinner on Friday evening, a capstone to a collegial and inspiring program. This year, we saw 5 young investigators recognized for their exemplary work, including the awarding of the inaugural "EGFR Resisters Research Summit Ivy Elkins Award" to the top-ranked presentation.

As part of the annual EGFR Resisters Research Summit tradition, Jill Feldman and Zosia Piotrowska participated in a recap video to provide members of the EGFR Resisters a highlight of the exciting work within EGFR-positive NSCLC. **Click here to view the video**.

> "This is a program that all of us look forward to each year…It's unique in the sense that it brings together patient advocates, faculty, and a wide variety of Young Investigators from all different backgrounds who are all united around a common goal of improving the lives of patients with lung cancer. It's truly a pleasure to be a part of this program."
>
> —Zofia Piotrowska, MD, MHS, Activity Chair

> "In addition to getting experience presenting their work at the Summit, the early career investigators truly benefit from the development of collaborative relationships, between themselves and the mentor judges…I really enjoyed interacting with the young investigators, getting to know them, and hearing about all the exciting work that they are doing. It is incredibly exciting since these investigators are the future of research—and EGFR-positive research."
>
> —Jill Feldman, Patient Advocate

Reflections from EGFR Resisters Co-Founder Jill Feldman

Reflecting on the 6th Annual Research Summit, I am struck by how much this Summit has shaped my advocacy experience. From the beginning, the goal of the Summit was clear: bring the next generation of EGFR researchers together with experienced mentors and advocates and create an environment that fosters collaborative efforts, connection, and, ultimately, progress. What I didn't expect was how much this experience would impact me. Each year, I have had the privilege of sitting in a room filled with brilliant, passionate researchers dedicating their careers to improving outcomes for people like me—something I never imagined I would see when I first got involved in advocacy in 2001. It has been inspiring to watch early career investigators present their work, receive meaningful feedback from mentor judges, and grow their careers. They are the future of EGFR-positive lung cancer research, and knowing that our Summit plays a small part in their growth is meaningful.

Beyond the science, what makes the Summit so unique is the collaboration. Witnessing deep discussions about work-life balance, grant writing, industry partnerships, and more reinforces that research doesn't happen in silos. It occurs through mentorship, honest feedback, support, and partnerships. The Summit has also reinforced the power of advocacy. It is more than raising awareness and funding research—it is actively creating an environment where fellows and junior faculty can network and grow. It is also about ensuring the next generation understands the urgency, humanity, and lived experience behind every data point.

To the mentor judges and all the investigators who have participated—thank you! You remind me year after year why we keep pushing forward.

Jill Feldman

About the EGFR Resisters Patient Advocacy Group

Established in 2017 by 7 original members—who draw on their experience as patients, survivors, caregivers, and healthcare providers—the EGFR Resisters represent a grassroots, patient-driven community dedicated exclusively to changing EGFR-mutated lung cancer into a chronic, manageable disease. With more than 5,851 members from 99 countries across the globe, the EGFR Resisters have become a well-established and widely-known oncogene driver group that is galvanizing research efforts in meaningful and unique ways, including data gathering efforts such as Project Priority and the EGFR Resisters Research Summit, which is a Young Investigator Forum that brings together established experts with the next generation of lung cancer researchers.

> "I was really struck by the patient-centered focus of this conference, and that really permeated through all the talks. It was such a refreshing reminder that this is truly what we're doing and why we're doing it. And we often get lost in the numbers and these charts and these curves, but at the end of the day, these are people—these are people with families and these are people with symptoms and quality of life—and I think that Jill and the other patient advocates really reminded me of that in a way that I think I'm going to take home and carry on through the rest of my career."

Celebrating the Legacy of Ivy Elkins

Ivy Elkins has touched the lives of thousands of people who have lung cancer, health professionals and researchers in the lung cancer space, and industry thought leaders all over the world through her advocacy work and as a patient with lung cancer. After being diagnosed with stage IV EGFR-positive lung cancer in 2013, Ivy consumed information to become an informed advocate for herself, but that drive for knowledge transformed her experience into a mission and fueled her passion for advocacy. In 2017, Ivy was one of the founding members of the EGFR Resisters, a community dedicated to supporting those affected by EGFR lung cancer and accelerating research to make it a manageable chronic disease. Her tireless dedication, inspiring leadership, and collaborative spirit drove the growth of the EGFR Resisters group, which now has nearly 6,000 members in 99 countries and has raised over $1 million to fund patient-driven, patient-funded research.

This year, the EGFR-RRS presented the first EGFR Resisters Research Summit Ivy Elkins Award to honor Ivy's legacy within the EGFR Resisters community. The award is presented to young investigators who demonstrate commitment to the pursuit of establishing innovative and foundational knowledge related to EGFR-mutated adenocarcinoma of the lungs. The EGFR-RRS will continue to honor the legacy of Ivy Elkins in patient advocacy and lung cancer research, and to memorialize her efforts by providing a platform that supports promising early career investigators through mentorship, facilitation of collegial connections, and coaching to refine presentation and research defense skills—all of which help promising early career scientists to exponentially increase the productivity of their research and publications and, by extension, continues Ivy's mission to improve and prolong the lives of patients with lung cancer.

2024 EGFR Resisters Research Summit Ivy Elkins Award

Catherine Meador, MD, PhD
Instructor in Medicine
Massachusetts General Hospital
Boston, Massachusetts

Detecting Small Cell Transformation in Patients with Advanced EGFR-mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling

Dr. Meador is a practicing thoracic medical oncologist with a clinical and translational research program focused on small cell lung cancer (SCLC) and other neuroendocrine cancers of the lung. She completed her MD-PhD at Vanderbilt University School of Medicine, where she studied mechanisms of resistance to targeted therapies in lung cancer for her graduate work. She then went on to complete her internal medicine residency at Brigham and Women's Hospital and medical oncology fellowship at Dana Farber Cancer Institute/Massachusetts General Hospital before joining the faculty at Massachusetts General Hospital Cancer Center. Her current research interests include development of new therapeutic strategies for de novo small cell lung cancer (SCLC) as well as SCLCs that result from histologic transformation.

> "Attending the EGFR-RRS allowed me to network with young investigator peers and establish future collaborations in the field of EGFR-mutant lung cancer. It also provided an invaluable forum for small-group interactions with senior mentors in the field, in a way other larger conferences don't allow for."
>
> "I am incredibly grateful for this award from the EGFR-RRS and plan to use the funds to continue my research efforts aimed towards improving both diagnostics and treatment of small cell transformation of EGFR-mutant NSCLC."

1st Runner-up

Jessica Stuart, MD
Medical Oncology Fellow
Memorial Sloan Kettering Cancer Center
New York, New York

Genomic Landscape of MTAP Deletions and Association with EGFR Alterations in Patients with Advanced Non–small Cell Lung Cancer

> "The research summit was an incredible experience! I was able to make connections with and learn from other fellows and attendings performing fascinating research. Many of these will turn into research collaborations that will help us in the fight against EGFR-mutant lung cancer."
>
> "This money will be used to further my research on MTAP deletions in EGFR-mutated lung cancer. Specifically, it will be used to perform technical aspects of my analysis (including immunohistochemical staining and FACETS analysis). It will also be used to support my attendance at conferences in which I will present this research and learn about other new developments in the field of EGFR-mutated lung cancer."

2nd Runner-up

Bobak Parang, MD, PhD
Assistant Professor of Medicine
Weill Cornell Medicine
New York, New York

Inhibiting SRPK2 Eradicates EGFR-mutant Drug-tolerant Persister Cells

"The EGFR Resisters Summit was a wonderful event. I met other junior investigators who were conducting exciting research, and I had the opportunity to meet senior faculty and patient advocates. I left the conference with new ideas and potential collaborations. I am grateful to the all the organizers."

"I plan to use this award to fund molecular studies aimed at understanding how EGFR-mutant lung cancer acquires drug resistance and if our drug combination strategy can prevent resistance to osimertinib."

2024 EGFR-RRS Faculty with Young Investigator Winners and Honorable Mention

Honorable Mentions

Christina M. Jimenez, BS
PhD Student
Vanderbilt University
Nashville, Tennessee

Evaluating the Structural Basis of NSCLC Mutant Dimerization within the Trans- and Juxtamembrane Region of EGFR and HER2

"Along with honing my presentation and scientific communication skills, participating in the EGFR-RRS provided me with the opportunity to meet and hear from clinical scientists on what drugs and combinations are currently testing and how their patients are responding. I also heard from patient advocates that have led and been at the forefront of EGFR research. Hearing their history and fight was emotional and powerful. I am early in my graduate school career and have a lot of decisions still to make on the direction of my research. Attending the EGFR-RRS provided me with a new clinical and translational perspective that I will consider as I decide next steps after graduate school. I'm grateful for the welcoming and friendly expert mentors, I have connected with them and fellow trainees on linkedin and am looking forward to following their research."

Donghoon Shin, MD
Internal medicine PGY-2
MetroWest Medical Center
Framingham, Massachusetts

Comprehensive Analysis of EGFR Exon 19 Deletion: Sequence, Epidemiology, and Molecular Architecture: Insights into NSCLC Therapy

"I'm really grateful for the opportunity to receive an Honorable Mention at the 6th Annual EGFR Resisters Research Summit (EGFR-RRS). It was an incredible experience to meet experts in the field and gain valuable insights that will help shape my future research. I also had the privilege of connecting with patient advocates, which was truly inspiring. Hearing their perspectives on how cancer research impacts patients gave me a deeper understanding of the real-world significance of our work. Their passion and dedication were a great source of motivation and have strengthened my commitment to continuing my career in this field. Overall, the summit has been a meaningful experience that will not only influence my future work but also reinforce my determination to grow as both a researcher and clinician."

2024 EGFR Resisters Research Summit Attendees

Louis Filipiak, MD, MBA
Medical Resident
Rush University
Chicago, Illinois

Examining Allostatic Load and Adiposity in Patients with EGFR Mutated Lung Cancer

Radhika Gutta, DO
Hematology and Oncology Fellow
Henry Ford Health System
Detroit, Michigan

Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR-mutant Lung Cancers

Mark Jeng, MD, PhD
Medical Oncology Fellow
Memorial Sloan Kettering Cancer Center
New York, New York

A Phase II Randomized Trial of Intracranial Consolidation and Deferral of RT in Patients with EGFR-mutant NSCLC Receiving Approved CNS-active Systemic Therapeutics: ICON-RT

Christina M. Jimenez, BS
PhD Student
Vanderbilt University
Nashville, Tennessee

Evaluating the Structural Basis of NSCLC Mutant Dimerization within the Trans- and Juxtamembrane Region of EGFR and HER2

Jonathan Lee, MD, MSc
Hematology Oncology Fellow
Weill Cornell Medicine
New York, New York

Impact of Osimertinib and Cranial Therapy on EGFR-Mutated Lung Cancer with Brain Metastasis: A Single Institution Retrospective Study

Ximeng Liu, PhD
Postdoctoral Fellow
MD Anderson Cancer Center
Houston, Texas

EGFR PACC Mutations Occur More Frequently as Compound Mutations with Better Responses to EGFR TKIs

Catherine Meador, MD, PhD
Instructor in Medicine
Massachusetts General Hospital
Boston, Massachusetts

Detecting Small Cell Transformation in Patients with Advanced EGFR-mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling

Arathi Nair, PhD
Postdoctoral Scholar, Research
Vanderbilt School of Medicine, Vanderbilt University
Nashville, Tennessee

Flow Cytometry-based High Throughput Assay for Characterization of EGFR Mutants

2024 EGFR Resisters Research Summit Attendees

Kelsey Pan, MD, MPH
Hematology Oncology Fellow
MD Anderson Cancer Center
Houston, Texas

Highly CNS-penetrant Tyrosine Kinase Inhibitors Improve Leptomeningeal Overall Survival in EGFR-mutant Non–small Cell Lung Cancer Patients with Leptomeningeal Disease

Bobak Parang, MD, PhD
Assistant Professor of Medicine
Weill Cornell Medicine
New York, New York

Inhibiting SRPK2 Eradicates EGFR-mutant Drug-tolerant Persister Cells

Emily Paton, MD
Resident Physician
Oregon Health & Science University
Portland, Oregon

Mapping of Patient-reported Outcome Items to Symptomatic Adverse Events of EGFR-TKIs in Non–small Cell Lung Cancer

Donghoon Shin, MD
Internal medicine PGY-2
MetroWest Medical Center
Framingham, Massachusetts

Comprehensive Analysis of EGFR Exon 19 Deletion: Sequence, Epidemiology, and Molecular Architecture: Insights into NSCLC Therapy

Jessica Stuart, MD
Medical Oncology Fellow
Memorial Sloan Kettering Cancer Center
New York, New York

Genomic Landscape of MTAP Deletions and Association with EGFR Alterations in Patients with Advanced Non–small Cell Lung Cancer

Fangdi Sun, MD
Hematology and Medical Oncology Fellow
Stanford University
Stanford, California

Pulse-dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-mutated Non–small Cell Lung Cancer

Sarah Waliany, MD, MS
Clinical Fellow
Massachusetts General Hospital
Boston, Massachusetts

Lung Carcinoid Tumors with Potentially Actionable Genomic Alterations and Responses to Targeted Therapies: Harnessing the Promise of Precision Oncology

"I was lucky to have experienced this!"

"Excellent and inspirational."

"I loved the intimate setting and getting to know everyone there well."

"It helped me build my professional network."

2024 EGFR Resisters Research Summit At-a-Glance

Henry Ford Health System
Detroit, Michigan

Massachusetts General Hospital
Boston, Massachusetts

MD Anderson Cancer Center
Houston, Texas

Memorial Sloan Kettering Cancer Center
New York, New York

MetroWest Medical Center
Framingham, Massachusetts

Oregon Health & Science University
Portland, Oregon

Rush University
Chicago, Illinois

Stanford University
Stanford, California

Vanderbilt University
Nashville, Tennessee

Weill Cornell Medicine
New York, New York



22 PARTICIPANTS

YOUNG INVESTIGATORS

EXPERT JUDGE MENTORS

PATIENT ADVOCATES

YOUNG INVESTGATORS



- FELLOW/POST DOCTORAL RESEARCHER
- JUNIOR FACULTY
- PhD/MD CANDIDATE

2024 EGFR Resisters Research Summit Faculty



Top row (*left to right*): John V. Heymach, MD, PhD; Stephen V. Liu, MD. ***Bottom row*** (*left to right*): Mary Jo Fidler, MD; Helena Yu, MD; and Zofia Piotrowska, MD, MHS

Zofia Piotrowska, MD, MHS (chair)
Assistant Professor
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

Mary Jo Fidler, MD
Alice Pirie Wirtz Professor of Medicine
Section Chief Medical Oncology
Rush University Medical Center
Chicago, Illinois

John V. Heymach, MD, PhD
Chair and Professor, Department of Thoracic/Head and Neck Medical Oncology
MD Anderson Cancer Center
Houston, Texas

Stephen V. Liu, MD
Associate Professor
Director, Thoracic Oncology
Georgetown University
Washington, DC

Helena Yu, MD
Associate Attending
Research Director, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

2024 Patient Advocates

Jill Feldman, MA
Lung Cancer Patient and Advocate
Co-Founder, EGFR Resisters

Diane Legg
Lung Cancer Advocate
Founder, LUNGSTRONG

Diane Legg has been an invaluable member of the EGFR Summit, sharing her journey, her wisdom, and her joy in living with all the faculty, Young Investigators, and staff. After 20 years as a patient and an advocate, Diane passed away peacefully on December 30, 2024.

2024 Professional Presentation Coach

Stephanie Roberson Barnard
Listen Write Present, LLC
Greensboro, North Carolina

2024 EGFR Resisters Research Summit Educational Highlights

Presentation Skills Enhancement Workshop



To augment the professional development aspects of the 2024 EGFR-RRS, participants had the opportunity to receive individual coaching sessions by a team of experts from Listen Write Present. Young investigators who participated in the one-on-one pre-program coaching sessions received expert advice and critique of their presentation and public speaking skills, and were given a copy of the book *Listen. Write. Present.*, which was written by the Listen Write Present team. In addition, the expert coaches provided participants with tips for effective navigation of expert Q&A and research defense.

Following coaching and abstract presentations, average participant confidence in their ability to present scientific information to peers increased from 2.47 to 3.0 on a 4-point scale. Similarly, average participant confidence in ability to defend their research increased from 2.35 to 2.89 following the event.

> "It has been incredibly helpful, not just for this presentation but also for improving my overall presentation skills."

Forum Highlights

- "Small group discussions"
- "Jill Feldman's personal anecdotes and experiences"
- "I loved the intimate setting and getting to know everyone there well"
- "I was deeply moved by the opening talk from the patient, which reminded me of the meaningful impact of the research I am doing"
- "Building connections with many well known members of the EGFR research community"
- "The small group sessions; the research presentations"
- "The small group discussions and meeting people from other research institutions"
- "The patient advocate stories"

What Participants Value Most

"I'm so glad to have had the opportunity to meet the judge mentors and learn from them...I found their career journeys and lessons to be incredibly insightful and relevant. This experience was truly valuable."

"This was such a foundational program for me. It was so helpful to present and discuss my research, and also to hear from my peers and see how they present research. I am extremely grateful for this opportunity!"

"Greatly enjoyed this opportunity to share my research with peers, and appreciate the number of faculty who were involved in this experience."

Mentoring Moments and Small-group Networking Sessions

For this year's EGFR-RRS, small groups of participants, along with faculty mentors, had the opportunity to introduce themselves in a small-group setting during the Mentoring Moment Small-group Discussions.

"I enjoyed the small-group conversations during the breaks between presentations. Engaging with professors, advocates, and fellows made the experience more refreshing and less tiring. These interactions also provided an opportunity to share and explore many interesting topics, which I found truly enjoyable."

GROUP TABLE TOPICS

- How to Approach a Career Track of Academic Leadership
- When to Say Yes? How to Say No? Seeking Mentorship
- Cooperative Groups Demystified
- Interacting with Pharma
- Social Media
- Juggling Early Career and Personal Life
- Clinical Trial Design
- Working with Patient Advocates
- Working with Professional Organizations
- Navigating the Grant Process and How to Obtain Funding

HOW ATTENDING THE SUMMIT WILL
Impact Young Investigators' Careers

Prior to the Summit, Young Investigators were asked what they hoped to gain from attending EGFR-RRS. One wrote that they looked forward to "the opportunity to meet both peers and future mentors in the field of EGFR lung cancer." Another stated that they hoped "to gain more confidence with public speaking and presentation skills." A third mentioned that they hoped "to build connections with peers and potential mentors within the lung cancer space, setting the stage for collaborations down the road." At the conclusion of the forum, 100% of respondents stated that participating in the EGFR-RRS will impact their current research and/or professional career, with noted gains relating to research ideas, collaborations, and faculty advice.

"This summit was truly amazing, and I learned so much not only from the mentors but also from other postdoc and fellow peers. It's such a fantastic group, with everyone contributing unique perspectives on the EGFR-mutant lung cancer that we're all passionate about. I would highly recommend this summit to other outstanding peers and sincerely hope I have the opportunity to attend again in the future."

"Attending has altered my opinion and view of translational medicine."

"I will strive to align my research more closely with clinically relevant questions."

"I learned a lot about the landscape of the EGFR community between researchers, providers, advocates, and everyone in between."

"It helped me build my professional network."

"New research ideas, mentors, and collaborators."

"It was deeply insightful to hear [patients'] perspectives on their hopes and expectations for cancer research."

"I will keep this in mind when deciding next steps for my career."

"I was deeply moved by the opening talk from the patient, which reminded me of the meaningful impact of the research I am doing.

"[EGFR-RRS] was not only a place for us to share some of the things that we were doing in MSK, but it was a place for me to meet everyone—and that was really important as a trainee."

Professional Updates from the 2023 EGFR-RRS Young Investigators

Research Publications, National Meeting Presentations, and Honors and Awards

The EGFR-RRS is a highly competitive research and professional development forum that strives to encourage, promote, and empower young investigators to forge collegial connections and acquire the necessary skills and relationships to increase their research productivity and catalyze their career trajectory. The following section is a glimpse at their accomplishments and research since attending the meeting in 2023.

Publications

Boulanger MC, Falade AS, Hsu K, et al. Patient and caregiver experience with the hope and prognostic uncertainty of immunotherapy: a qualitative study. *JCO Oncol Pract*. 2024:OP2400299.

Boulanger MC, Krasne MD, Gough EK, et al. Outpatient embedded palliative care for patients with advanced thoracic malignancy: a retrospective cohort study. *Curr Oncol*. 2024;31(3):1389–1399.

Boulanger MC, Schneider JL, Lin JJ. Advances and future directions in ROS1 fusion-positive lung cancer. *Oncologist*. 2024;29(11):943–956.

Boulanger MC, Tieger MG, Eliott D, Yee AJ. Intravitreal aflibercept confounds interpretation of plasma VEGF (vascular endothelial growth factor) levels in POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome. *EJHaem*. 2024;5(2):421–422.

Durbin SM, Lundquist D, Pelletier A, [...] **Boulanger M**, et al. Financial toxicity in early-phase cancer clinical trial participants. *Cancer*. 2025;131(1):e35586.

Falade AS, **Boulanger MC**, Hsu K, et al. Learning about and living with toxicity: a qualitative study of patients receiving immune checkpoint inhibitors for melanoma or lung cancer and their caregivers. *Support Care Cancer*. 2024;32(10):684.

Hsu ML, **Boulanger MC**, Olson S, et al. Unmet needs, quality of life, and financial toxicity among survivors of lung cancer. *JAMA Netw Open*. 2024;7(4):e246872.

Hsu ML, Guo MZ, Olson S, Eaton C, **Boulanger M**, et al. Lung cancer survivorship: physical, social, emotional, and medical needs of NSCLC survivors. *J Natl Compr Canc Netw*. 2024;22(1D):e237072.

Boulanger MC, Petrillo LA, Temel JS. Listen to the patient: integrating patient-reported outcomes into clinical care. *J Natl Cancer Inst*. 2023;115(12):1451–1453.

Chang AEB, Piper-Vallillo AJ, Mak RH, et al. The ASCENT trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC. *Oncologist*. 2024;29(7):609–618.

Chang AEB, Potter AL, Yang CJ, Sequist LV. Early detection and interception of lung cancer. *Hematol Oncol Clin North Am*. 2024;38(4):755–770.

Simon J, Mikhael P, Graur A, **Chang AEB**, et al. Significance of image reconstruction parameters for future lung cancer risk prediction using low-dose chest computed tomography and the open-access sybil algorithm. *Invest Radiol*. October 23, 2024. [Epub ahead of print]

Dreyer MS, Mulcahy M, Kocherginsky M, et al. A phase II study of FOLFOX combined with nab-paclitaxel in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: a Big Ten Cancer Research Consortium trial. *Oncologist*. 2024;29(12):1044–1050.

Matossian MD, Shiang C, Dolcen DN, **Dreyer M**, et al. High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration. *Breast Cancer Res Treat*. November 23, 2024. [Epub ahead of print]

Russell AM, Pack AP, Bailey SC, Weldon CB, **Dreyer MS**, et al. A local perspective on internal, external, and reflexive biomarker testing processes for lung cancer in an academic medical center. *Cancer*. 2024;130(12):2085–2090.

Ferrarone JR, Thomas J, Unni AM, [...] **Gardner EE**, et al. Genome-wide CRISPR screens in spheroid culture reveal that the tumor suppressor LKB1 inhibits growth via the PIKFYVE lipid kinase. *Proc Natl Acad Sci U S A*. 2024;121(21):e2403685121.

Gardner EE, Earlie EM, Li K, et al. Lineage-specific intolerance to oncogenic drivers restricts histological transformation. *Science*. 2024;383(6683):eadj1415.

Katti A, Vega-Pérez A, Foronda M, [...] **Gardner EE**, et al. Generation of precision preclinical cancer models using regulated in vivo base editing. *Nat Biotechnol*. 2024;42(3):437–447.

Gomez-Randulfe I, Leporati R, **Gupta B**, et al. Recent advances and future strategies in first-line treatment of ES-SCLC. *Eur J Cancer*. 2024;200:113581.

Gupta B, Gosa Barrett L, Liu SV. NRG1 Fusions in NSCLC: Being eNRGy Conscious. *Lung Cancer (Auckl)*. 2024;15:143–148.

Henick BS, **Herzberg BO**, Concepcion-Crisol CP, Taylor AM. Controlled chaos: parsing acquired immunoresistance in lung cancer. *J Clin Oncol*. 2024;42(11):1211–1214.

Le X, Patel JD, Shum E, [...] **Herzberg B**, et al. A multicenter open-label randomized phase II study of osimertinib with and without ramucirumab in tyrosine kinase inhibitor-naïve *EGFR*-mutant metastatic non-small cell lung cancer (RAMOSE trial). *J Clin Oncol*. October 8, 2024. [Epub ahead of print]

Zhou JJ, Chen LN, Lehan T, **Herzberg B**, et al. Severe scalp ulcerations and granulomata during treatment with amivantamab. *Curr Probl Cancer Case Rep.* 2024;13:100273.

Chen F, Ding K, Priedigkeit N, Elangovan A, **Levine KM,** et al. Single-cell transcriptomic heterogeneity in invasive ductal and lobular breast cancer cells [Published correction appears in: *Cancer Res.* 2024;84(24):4298]. *Cancer Res.* 2021;81(2):268–281.

Moorthi S, Paguirigan A, Itagi P, [...] **Levine KM**, et al. The genomic landscape of lung cancer in never-smokers from the Women's Health Initiative. *JCI Insight*. 2024;9(17):e174643.

Maheshwari S, Gentzler RD. Implications for practice: phase II/III trial of carboplatin and irinotecan for elderly patients with extensive-stage small-cell lung cancer in Japan. *J Thorac Dis*. 2024;16(9):6342–6346.

Skoulidis F, Araujo HA, Do MT, [...] **Memmott R**, et al. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. *Nature*. 2024;635(8038):462–471.

Wong A, Riley M, Zhao S, [...] **Memmott RM**, et al. Association between pretreatment chest imaging and immune checkpoint inhibitor pneumonitis among patients with lung cancer. *J Natl Compr Canc Netw*. 2023;21(11):1164–1171.e5.

Elkrief A, Montesion M, Sivakumar S, [...] **Quintanal Villalonga Á**, et al. Intratumoral escherichia is associated with improved survival to single-agent immune checkpoint inhibition in patients with advanced non-small-cell lung cancer. *J Clin Oncol*. 2024;42(28):3339–3349.

"The EGFR-RRS provided excellent networking with both junior and senior researchers in the field. They imparted valuable advice on next steps for my research as well as opportunities for collaboration."

Hiatt JB, Doebley AL, Arnold HU, [...] **Quintanal Villalonga Á**, et al. Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions. *Sci Adv*. 2024;10(15):eadk2082.

Quintanal-Villalonga Á. An identity crisis for lung cancer cells. *Sci Transl Med*. 2024;16(760):eadp9616.

Quintanal-Villalonga Á, Kawasaki K, Redin E, et al. CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation. *Signal Transduct Target Ther*. 2024;9(1):189.

Redin E, **Quintanal-Villalonga Á**, Rudin CM. Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity. *Trends Cancer*. 2024;10(10):935–946.

Redin E, Sridhar H, Zhan YA, [...] **Quintanal-Villalonga Á**, Rudin CM. SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing [Published correction appears in: *J Hematol Oncol*. 2024;17(1):89]. *J Hematol Oncol*. 2024;17(1):58.

Taniguchi H, Chakraborty S, Takahashi N, [...] **Quintanal-Villalonga Á**, et al. ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer. *Sci Adv*. 2024;10(39):eado4618.

Cheunkarndee T, Guo MZ, Houseknecht S, [...] **Scott SC.** First-line osimertinib for lung cancer with uncommon EGFR exon 19 mutations and EGFR compound mutations. *JTO Clin Res Rep*. 2024;5(6):100686.

Murray JC, Sivapalan L, Hummelink K, [...] **Scott SC**, et al. Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer. *Clin Cancer Res*. 2024;30(2):389–403.

Nakazawa M, Harada G, Ghanem P, [...] **Scott SC**,et al. Impact of tumor-intrinsic molecular features on survival and acquired tyrosine kinase inhibitor resistance in ALK-positive NSCLC. *Cancer Res Commun*. 2024;4(3):786–795.

Barsouk A, Elghawy O, Heidlauf A, [...] **Sun L**, et al. Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) treated with osimertinib (osi) vs. afatinib or erlotinib. *Lung Cancer*. 2024;195:107926.

Barsouk A, Friedes C, Iocolano M, [...] **Sun L**, et al. Plunging into the PACIFIC: outcomes of patients with unresectable KRAS-mutated non-small cell lung cancer following definitive chemoradiation and durvalumab consolidation. *Clin Lung Cancer*. 2024;25(3):e161–e171.

Demissei BG, Ko K, Huang A, [...] **Sun L**, et al. Social determinants of health mediate racial disparities in cardiovascular disease in men with prostate cancer. *JACC CardioOncol*. 2024;6(3):390–401.

Elghawy O, Barsouk A, Heidlauf A, [...] **Sun L**. Single-institution experience of larotrectinib therapy for patients with *NTRK* fusion-positive thyroid carcinoma. *J Endocr Soc*. 2024;8(10):bvae158.

Elghawy O, Barsouk A, Xu J, [...] **Sun L**. Real word outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma. *Eur Thyroid J*. 2024;13(6):e240225.

Friedes C, Iocolano M, Lee SH, [...] **Sun LL**, et al. Patterns of failure, low-volume relapse, and subsequent ablative management in locally advanced non-small cell lung cancer treated with definitive chemoradiation and consolidation immune checkpoint inhibitors. *Int J Radiat Oncol Biol Phys*. 2024;118(5):1435–1444.

Friedes C, Iocolano M, Lee SH, [...] **Sun LL**, et al. The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC. *Radiother Oncol*. 2024;190:110030.

Hanna GJ, Jabalee J, Lukens JN, **Sun L**, et al. Circulating tumor tissue modified viral (TTMV)-HPV DNA in recurrent, metastatic HPV-driven oropharyngeal cancer. *Oral Oncol*. 2024;158:107002.

Iocolano M, Yegya-Raman N, [...] **Sun L**, et al. Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era. *Cancer*. 2024;130(11):2031–2041.

Marmarelis ME, Scholes DG, McGrath CM, [...] **Sun L**, et al. Brief report: impact of reflex testing on tissue-based molecular genotyping in patients with advanced non-squamous non-small cell lung cancer. *Clin Lung Cancer*. 2024;25(3):262–265.e2.

Marmarelis ME, Scholes DG, McWilliams TL, [...] **Sun L**, et al. Electronic medical record-based nudge intervention to increase comprehensive molecular genotyping in patients with metastatic non-small cell lung cancer: results from a prospective clinical trial. *JCO Oncol Pract*. 2024;20(12):1620–1628.

Patel AM, Haleem A, Revercomb L, [...] **Sun LL**, et al. Primary site surgical resection in cM1 oral cavity squamous cell carcinoma. *Laryngoscope Investig Otolaryngol*. 2024;9(5):e70000.

Reibel JB, **Sun LL**, Parikh RB, et al. Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer. *J Natl Cancer Inst*. 2024:djae307.

Sannigrahi MK, Cao AC, Rajagopalan P, **Sun L**, et al. A novel pipeline for prioritizing cancer type-specific therapeutic vulnerabilities using DepMap identifies PAK2 as a target in head and neck squamous cell carcinomas. *Mol Oncol*. 2024;18(2):336–349.

Stalker M, Marmarelis M, Langer C, [...] **Sun L**. Outcomes following treatment for progression in patients treated with durvalumab consolidation in LA-NSCLC. *Clin Lung Cancer*. November 10, 2024. [Epub ahead of print]

Sun L, Cohen RB, D'Avella CA, et al. Overall survival, treatment duration, and rechallenge outcomes with ICI therapy for recurrent or metastatic HNSCC. *JAMA Netw Open*. 2024;7(8):e2428526.

Sun L, Cohen RB, Dimitrios Colevas A. Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). *Oral Oncol*. 2024;158:106997.

Sun L, Handorf EA, Zhou Y, et al. Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels. *Lung Cancer*. 2024;190:107510.

Yegya-Raman N, Berman AT, [...] **Sun L**, et al. Phase 2 trial of consolidation pembrolizumab after proton reirradiation for thoracic recurrences of non-small cell lung xancer. *Int J Radiat Oncol Biol Phys*. 2024;119(1):56–65.

Yegya-Raman N, Friedes C, Lee SH, [...] **Sun L**, et al. Pneumonitis rates before and after adoption of immunotherapy consolidation in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiation. *Int J Radiat Oncol Biol Phys*. 2024;118(5):1445–1454.

Yegya-Raman N, Ho Lee S, Friedes C, [...] **Sun L**, et al. Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation. *Radiother Oncol*. 2024;190:110005.

Lu JS, Cao AC, Shimunov D, **Sun L**, et al. Functional outcomes in patients with human papillomavirus-associated oropharyngeal squamous cell cancer treated with trimodality therapy. *Laryngoscope*. 2023;133(11):3013–3020.

Collaborative Publications among EGFR-RRS 2023 Young Investigators

Grady CB, Hwang WT, Reuss JE, [...] **Herrmann A**, [...] **Sun L**, Marmarelis ME. Determining line of therapy from real-world data in non-small cell lung cancer. *Pharmacoepidemiol Drug Saf*. 2024;33(12):e70049.

Tompkins W, Grady CB, Hwang WT, [...] **Herrmann A**, [...] **Sun L**. Characteristics of long-term survivors with EGFR-mutant metastatic NSCLC. *JTO Clin Res Rep*. 2024;5(8):100669.

Rekhtman N, Tischfield SE, Febres-Aldana CA, [...] **Herzberg BO**, [...] **Quintanal-Villalonga Á**, et al. Chromothripsis-mediated small cell lung carcinoma. *Cancer Discov*. 2025;15(1):83–104.

Presentations

European Lung Cancer Congress, European Society for Medical Oncology (ESMO) 2024
March 20–23, 2024; Prague, Czech Republic

Quintanal-Villalonga Á, Costa E, Wohlheiter C, et al. SMARCA4 inactivation drives aggressiveness in STK11/KEAP1 co-mutant lung adenocarcinomas through the induction of TGFβ. Abstract 228P.

American Association for Cancer Research (AACR) Annual Meeting 2024
April 5–10, 2024; San Diego, California

Quintanal-Villalonga Á, Uddin F, Kawasaki K, et al. CDC7 inhibition prevents neuroendocrine transformation in the lung and prostate through MYC degradation. Abstract 2004.

2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31–June 4, 2024; Chicago, Illinois

Boulanger MC, Falade AS, Hsu K, et al. Patient and caregiver experience with the hope and prognostic uncertainty of immunotherapy: a qualitative study. Abstract 12010.

Maheshwari S, Smilnak G, Singh R, et al. Next-generation sequencing (NGS) completion and timeliness using reflex testing protocol for patients with stage II-III non-squamous non-small cell lung cancer (NS-NSCLC). Abstract 8060.

Quintanal-Villalonga Á, Kawasaki K, Redin E, et al. Effect of CDC7 inhibition and MYC degradation on neuroendocrine transformation in the lung and prostate cancer. Abstract e20105.

Shahid MA, Kulkami RB, Albusoul L, et al. Evaluation and treatment response in patients with hormone receptor-positive, HER2 low metastatic breast cancer: a single center retrospective analysis. Abstract e13158.

Sun L, Fayette J, Salas S, et al. Tisotumab vedotin in head and neck squamous cell carcinoma: updated analysis from innovaTV 207 Part C. Abstract 6012.

Cold Spring Harbor Laboratory (CSHL) Mechanisms & Models of Cancer 2024
August 13–17, 2024; Cold Spring Harbor, New York

Gardner EE, Earlie EA, Laughney AM, et al. How does a transformed cell shape its pulmonary niche? Poster presentation.

2024 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer
September 7–10, 2024; San Diego, California

Gupta B, Baca Y, Hubbard G, et al. HER3 expression across genomic subsets of NSCLC. Abstract P1.06B.16.

Gupta B, Zaemes JP, Yeung V, et al. A phase II study of vobramitamab duocarmazine in patients with relapsed or refractory extensive-stage small cell lung cancer. Abstract EP.13A.03.

Herrmann A, Bazhenova L, Janin S. TIME TOX lung: retrospectively quantifying the time toxicity of lung cancer clinical trials. Abstract MA10.13.

Memmott R, Gheeya J, Wei L, et al. A phase Ib study of osimertinib and tegaviivint as first-line therapy in patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC). Abstract P3.12D.01.

36th European Organisation for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium on Molecular Targets and Cancer Therapeutics 2024
October 23–25, 2024; Barcelona, Spain

Herzberg B, Johnson M, Kim CG, et al. Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC). Abstract No. 501LBA.

Honors and Awards

Mary C. Boulanger, MD

2024 Conquer Cancer, American Society of Clinical Oncology Annual Meeting Merit Award

2024 Cancer Survivorship Research Grant, Massachusetts Society of Clinical Oncologists

CECONCEPTS
HEALTHCARE EDUCATION

Start Planning for 2025!

7TH ANNUAL EGFR RESISTERS RESEARCH SUMMIT

Abstract submission deadline and forum details for EGFR-RRS 2025 coming soon. To be notified when the Call for Abstracts is distributed, please email **info@ceconcepts.com**.

Visit the Summit **website** for all things EGFR-RRS!

Follow us on X **@EGFRSummit**

"I was a little bit nervous applying [for consideration] because I felt like maybe my research wasn't at the stage that I wanted to present it or talk about it, but I'm so glad I presented it and I'm so glad I came...If you're thinking about it, just apply, because your research is one part of it. All the other parts—the networking and hearing everyone else speak and practicing your own presentation—that can be done regardless of what you're presenting. So, I think if you're on the fence and you're thinking about it, you're not sure about your research, just do it. **Just do it.**"